HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Deafness (Deaf Mutism)

A general term for the complete loss of the ability to hear from both ears.
Also Known As:
Deaf Mutism; Deaf-Mutism; Deafness, Acquired; Hearing Loss, Complete; Hearing Loss, Extreme; Acquired Deafness; Complete Hearing Loss; Deafness, Prelingual; Extreme Hearing Loss; Permanent, Deafness; Permanent, Hearing Loss; Permanents, Deafness; Deafness Permanent; Hearing Loss Permanent; Prelingual Deafness
Networked: 5416 relevant articles (196 outcomes, 473 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Hearing Loss (Hearing Impairment)
2. Tinnitus
3. Mixed Conductive-Sensorineural Hearing Loss
4. Bilateral Hearing Loss
5. Vertigo (Positional Vertigo)

Experts

1. Guan, Min-Xin: 56 articles (10/2022 - 07/2002)
2. Friedman, Thomas B: 35 articles (04/2022 - 05/2003)
3. Petit, Christine: 31 articles (01/2021 - 11/2000)
4. Lenarz, Thomas: 28 articles (01/2022 - 06/2006)
5. Dai, Pu: 27 articles (02/2022 - 02/2006)
6. Skarzynski, Henryk: 26 articles (01/2022 - 09/2006)
7. Avraham, Karen B: 26 articles (01/2021 - 03/2002)
8. Van de Heyning, Paul: 24 articles (05/2022 - 09/2008)
9. Smith, Richard J H: 24 articles (01/2022 - 05/2002)
10. Zheng, Jing: 23 articles (01/2021 - 03/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Deafness:
1. Silver Sulfadiazine (SSD)FDA LinkGeneric
2. Adrenal Cortex Hormones (Corticosteroids)IBA
3. Dexamethasone (Maxidex)FDA LinkGeneric
4. SteroidsIBA
5. 2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA
6. Thiamine (Aneurin)FDA Link
7. SolutionsIBA
8. Proteins (Proteins, Gene)FDA Link
01/01/2020 - "This review: 1) documents AAV dual and triple vector strategies currently employed in a variety of tissues, and highlights the advantages and disadvantages of each method; 2) describes the first successful studies using the dual vector approach to restore hearing and prevent deafness in a mouse model of non-syndromic deafness due to absence of the otoferlin protein function, and the implications of these findings for the future of gene therapy in the human inner ear; and 3) highlights additional different deafness genes that could be potential future targets for gene therapy using the dual vector approach."
04/01/2019 - "A combination of human induced pluripotent stem cell (hiPSC) technology with clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR-associated protein (Cas)9-mediated gene editing may provide a promising tool to study gene function and treat hereditary deafness in humans. "
03/01/2019 - "This study aimed to investigate the role of RNF8 (RING finger protein 8) in DNA damage repair in mice of different ages, and to provide new insight into the pathology and treatment of senile deafness. "
02/01/2019 - "In summary, this study revealed two compound heterozygous mutations (c.1174A>T/c.1181delTCT; c.919- 2A>G/c.1023insC) in Pendrin protein, which might account for the deafness of the two probands clinically diagnosed with EVA. "
01/01/2018 - "Recent studies have shown it is composed of a small set of proteins, some of which are only produced at high levels in the ear and many of which are the products of genes that, when mutated, cause nonsyndromic forms of human hereditary deafness. "
9. Nerve Growth Factors (Neurotrophins)IBA
10. AntioxidantsIBA

Therapies and Procedures

1. Cochlear Implants (Cochlear Implant)
2. Cochlear Implantation
3. Therapeutics
4. Hearing Aids (Hearing Aid)
5. Electrodes (Electrode)